web analytics

Fetomaternal Medicine

Tuesday, March 22, 2016

08:30-10:00 CESAREAN SECTION
Chairpersons Aris Antsaklis, Greece
Julia Unterscheider, Australia
08:30-09:30 Debate: There is no place for VBAC: Once a Caesarean, always a Caesarean
Not True: Aris Antsaklis, Greece
True: Ben W.J. Mol, Australia
Discussion
09:30-10:00 All pregnant women should be offered the possibility of a Caesarean section
Julia Unterscheider, Australia
10:00-10:30 Coffee Break
10:20-11:50 TOCOLYSIS
Chairpersons Shaun Brennecke, Australia
Ben W.J. Mol, Australia
10:20-11:20 Debate: There is no place for tocolysis in threatened preterm labour
Pro: Ryan Hodges, Australia
Con: Jon Hyett, Australia
Discussion
11:20-11:50 Routine cervical length by TV scan at mid-gestation for preterm delivery screening
Penny Sheehan, Australia
11:50-12:10 Break
12:10-13:40 CELL-FREE DNA (cfDNA) TESTING
Supported by Roche
Capsule Cell-free DNA (cfDNA) testing is revolutionizing prenatal care by providing a simple, highly accurate, non-invasive screening method for aneuploidy. As demand for cfDNA testing is rising quickly, an increasing number of physicians are offering Non-invasive prenatal testing (NIPT) in their practice. However questions around clinical implementation, patient counseling and future applications remain. What do you and your patients need to know about cfDNA testing? How do we best integrate cfDNA testing into our clinical practice? Is expanding the indications for cfDNA testing useful? Where do we go from here?
Chairpersons Ricardo Palma-Dias, Australia
Maximilian Schmid, Austria
Screening in pregnancy: Traditional screening for aneuploidy and prediction of preeclampsia
Jon Hyett, Australia
CfDNA testing technology and biology: What do you really need to know?
Graeme Suthers, Australia
Implementation of cfDNA testing in clinical practice: Principles and guidelines
Fabricio Costa, Australia
Non-invasive prenatal testing: Future perspectives
Maximilian Schmid, Austria
13:40-14:30 Lunch Break
14:30-16:00 PROGESTERONE SUPPORT DURING PREGNANCY
Capsule Progesterone use to arrest premature labour is being used with increasing frequency
Chairpersons Ryan Hodges, Australia
John Regan, Australia
14:30-14:45 Debate: Progesterone should be the cornerstone of prevention of preterm birth
Pro: Penny Sheehan, Australia
Con: Euan Wallace, Australia
Discussion
15:15-15:40 Is progesterone effective in PTL and multiple pregnanices?
Ben W.J. Mol, Australia
15:40-16:00 Progesterone for early pregnancy loss
Salim Daya, Canada
16:00-16:30 Coffee break
16:30-18:00 US: PRENATAL DIAGNOSIS
Chairpersons Fabricio Costa, Australia
Jon Hyett, Australia
16:30-16:50 Is routine 3rd trimester scanning and cerebro-placental ratio (CPR) justifiable in clinical practice?
Fergus Scott, Australia
16:50-17:15 Fetal echogenic lung lesions: Controversies in nomenclature, follow-up and treatment
Fabricio Costa, Australia
17:15-17:35 Is laser recommended for stage I twin-to-twin transfusion syndrome (TTTS)?
Mark Teoh, Australia
17:35-18:00 Amniocentesis to define a fetal inflammatory response in premature rupture of membranes (PPRoM) / spontaneous preterm labour (sPTL)
Jon Hyett , Australia

Wednesday, March 23, 2016

08:30-10:00 OPERATIVE OBSTETRICS
Chairperson Aris Antsaklis, Greece
John Campbell, Australia
08:30-09:15 Debate: Should we keep using Forceps and Vacuum?
Yes: John Regan, Australia
No: Aris Antsaklis, Greece
Discussion
09:15-09:35 Myomectomy during CS
Zion Ben Rafael, Israel
09:35-10:00 Surgical management of placental adhesion
Elske Posma, Australia
10:00-10:20 Coffee Break
10:20-11:50 PREMATURE LABOUR
Capsule Prevention of premature labour remains one of the major challenges in obstetrics
Chairpersons Ben W.J. Mol, Australia
Ryan Hodges,
Australia
10:20-11:20 Debate:
Proposition: Testing for fetal fibronectin should be done in all women with threatened preterm labour
Shaun Brennecke, Australia
Opposition: Ben W.J. Mol, Australia
Discussion
11:20-11:50 The pros and cons of corticosteroids should be used prior to elective CS near term
Julia Unterscheider, Australia
11:50-12:10 Break
12:10-13:40 PREECLAMPSIA
Capsule The ability to predict changes in Markers, weeks before the onset of preeclampsia is the first step in offering prevention plan. What is the medical benefit of prediction?
Chairpersons Penny Sheehan, Australia
Shaun P. Brennecke, Australia
12:10-12:30 Could close surveillance of the patient at risk of preeclampsia prevent the pathology or save maternal and fetal life?
Shaun P. Brennecke, Australia
12:30-12:55 The best method to predict Hypertension
Euan Wallace, Australia
12:55-13:40 Debate: Is LMWH useful in the prevention of preeclampsia?
Yes: Gustaaf Dekker, Australia
No: Joanne Said, Australia
Discussion
13:40-14:30 Lunch break
14:30-16:00 OBESITY IN PREGNANCY
Capsule Obesity was declared an epidemic, obstetric complications are now being recognized. What are the implications?
Chairpersons Michael Permezel, Australia
Alexis Shub, Australia
14:30-15:00 What should be the target birth weight?
Michael Permezel, Australia
15:00-15:30 The new ADIPS criteria for GDM should be applied universally
Alexis Shub, Australia
15:30-16:00 Improving perinatal health care for Aboriginal women as a crucial strategy to address inter-generational diabetes
Jacqueline Boyle, Australia
16:00-16:30 Coffee Break
16:30-18:00 FETAL MONITORING
Capsule Fetal monitoring remains controversial despite years of use and computerized improvements. Where do we come from? Where are we going? Can we do without it or should we keep improving the technique?
Chairpersons Micahel Premezel, Australia 
Aris Antsaklis
, Greece
16:30-17:00 The new FIGO guidelines on FHR monitoring
Henry G. Murray, Australia
17:00-17:30 Auscultation vs. FHR
Aris Antsaklis, Greece
17:30-18:00 Improving pregnancy care for Aboriginal and Torres Strait Islander women: a national continuous quality improvement project
Jacqueline Boyle, Australia